Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Techne (TECH) Inventory (2016 - 2025)

Bio-Techne has reported Inventory over the past 16 years, most recently at $205.4 million for Q4 2025.

  • Quarterly results put Inventory at $205.4 million for Q4 2025, up 9.06% from a year ago — trailing twelve months through Dec 2025 was $205.4 million (up 9.06% YoY), and the annual figure for FY2025 was $189.4 million, up 5.41%.
  • Inventory for Q4 2025 was $205.4 million at Bio-Techne, up from $203.2 million in the prior quarter.
  • Over the last five years, Inventory for TECH hit a ceiling of $205.4 million in Q4 2025 and a floor of $110.0 million in Q1 2021.
  • Median Inventory over the past 5 years was $175.6 million (2023), compared with a mean of $163.8 million.
  • Biggest five-year swings in Inventory: skyrocketed 32.1% in 2023 and later fell 0.56% in 2024.
  • Bio-Techne's Inventory stood at $121.9 million in 2021, then surged by 31.49% to $160.2 million in 2022, then rose by 12.86% to $180.8 million in 2023, then grew by 4.17% to $188.4 million in 2024, then grew by 9.06% to $205.4 million in 2025.
  • The last three reported values for Inventory were $205.4 million (Q4 2025), $203.2 million (Q3 2025), and $189.4 million (Q2 2025) per Business Quant data.